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Objectives. The anti-dsDNA antibodies are a marker for Systemic Lupus Erythematosus (SLE) and 70–98% of patients test positive.
We evaluated the demographic, clinical, laboratory, and therapeutical features of a monocentric SLE cohort according to the anti-
dsDNA status. Methods. We identified three groups: anti-dsDNA + (persistent positivity); anti-dsDNA ± (initial positivity and
subsequent negativity during disease course); anti-dsDNA − (persistent negativity). Disease activity was assessed by the European
Consensus LupusActivityMeasurement (ECLAM).Results.We evaluated 393 patients (anti-dsDNA+: 62.3%; anti-dsDNA±: 13.3%;
anti-dsDNA −: 24.4%). The renal involvement was significantly more frequent in anti-dsDNA + (30.2%), compared with anti-
dsDNA ± and anti-dsDNA − (21.1% and 18.7%, resp.; 𝑃 = 0.001). Serositis resulted significantly more frequent in anti-dsDNA −
(82.3%) compared to anti-dsDNA + and anti-dsDNA ± (20.8% and 13.4%, resp.; 𝑃 < 0.0001). The reduction of C4 serum levels
was identified significantly more frequently in anti-dsDNA + and anti-dsDNA ± (40.0% and 44.2%, resp.) compared with anti-
dsDNA − (21.8%, 𝑃 = 0.005). We did not identify significant differences in the mean ECLAM values before and after modification
of anti-dsDNA status (𝑃 = 0.7). Conclusion. Anti-dsDNA status influences the clinical and immunological features of SLE patients.
Nonetheless, it does not appear to affect disease activity.
1. Introduction
Systemic Lupus Erythematosus (SLE) is an autoimmune
disease, characterized by the production of a wide range of
autoantibodies, resulting from polyclonal B cells activation,
impaired apoptotic pathways, or idiotypic network dysregu-
lation [1–5].
The anti-double stranded DNA antibodies (anti-dsDNA)
are considered a specific marker for SLE [6]. Due to the
high frequency (ranging from 70% to 98%), sensitivity,
and specificity (57.3% and 97.4%, resp.), the presence of
these autoantibodies could be virtually diagnostic for SLE
[2, 6]. Moreover, their identification in other pathological
conditions and in healthy subjects is very rare (less than
0.5%) [7]. Furthermore, the identification of anti-dsDNA in
SLE patients several years before disease onset suggests their
involvement towards a clinically overt disease [8].
Several lines of evidence demonstrate the pathogenic role
of anti-dsDNA antibodies. In particular, these autoantibodies
have been associated with kidney involvement, as demon-
strated by their deposition in several renal structures in
SLE patients with active nephritis, that is, glomeruli, suben-
dothelial and subepithelial spaces, mesangium, basement
membrane, and tubules [9]. Moreover, by the interaction
with toll-like receptor 9 (TLR 9), anti-dsDNA complexed
with DNA could determine the activation of dendritic cells,
with consequent B and T-cells activation and the release
of proinflammatory cytokines [10]. Data from the literature
demonstrate that the increase in anti-dsDNA serum levels
could precede the relapse of disease, especially in terms of
renal disease exacerbation [11, 12].
Despite the central role of these antibodies in the disease
pathogenesis, a percentage of SLE patients, ranging from 2
to 30%, result negative for anti-dsDNA [7]. In the light of
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these considerations, the present study evaluated the clinical
and laboratory features and therapeutical approach in a large
monocentric SLE cohort, grouping patients according to their
anti-dsDNA status and performing a comparison among the
different subgroups.
2. Patients and Methods
We enrolled SLE patients referred to the Lupus Clinic of the
Rheumatology Unit, Sapienza University of Rome (Sapienza
Lupus Cohort). The diagnosis was performed according to
the revised 1997 American College of Rheumatology (ACR)
criteria [13].
Patients provided a written informed consent at the time
of the first visit. The local ethical committee of “Policlinico
Umberto I,” Rome, Italy, approved the study. At each visit,
the patients underwent a complete physical examination.The
clinical and laboratory data were collected in a standard-
ized, computerized, and electronically filled form, including
demographics, past medical history with date of diagnosis,
comorbidities, and previous and concomitant treatments.
We assessed the disease activity by using the European
Consensus Lupus Activity Measurement (ECLAM) [14],
since this index does not include the measurement of anti-
dsDNA antibodies.
2.1. Clinical Evaluation of SLE Patients. According to 1997
ACR revised criteria [13], we registered the presence of the
following SLE manifestations:
(i) Skin Involvement. Malar rash (fixed erythema, flat or
raised, over themalar eminences, tending to spare the
nasolabial folds), discoid rash (erythematous raised
patches with adherent keratotic scaling and follicu-
lar plugging; atrophic scarring may occur in older
lesions), and photosensitivity (skin rash as a result
of unusual reaction to sunlight, by patient history or
physician observation).
(ii) Oral Ulcers. Oral or nasopharyngeal ulceration obs-
erved by physician.
(iii) Serositis. Pleuritis (convincing history of pleuritic
pain or rubbing heard by a physician or evidence
of pleural effusion) or pericarditis (documented by
electrocardiogram or rub or evidence of pericardial
effusion).
(iv) Kidney Involvement. Persistent proteinuria >0.5
grams per day or > than 3+ if quantitation not perfor-
med or cellular casts (red cell, hemoglobin, granular,
tubular, or mixed).
(v) Neurologic Disorder. Seizures (in the absence of
offending drugs or known metabolic derangements,
e.g., uremia, ketoacidosis, or electrolyte imbalance) or
psychosis (in the absence of offending drugs or known
metabolic derangements, e.g., uremia, ketoacidosis,
or electrolyte imbalance).
(vi) Hematologic Disorder. Hemolytic anemia with reticu-
locytosis or leukopenia <4.000/mm3 on ≥2 occasions
or lymphopenia <1.500/mm3 on ≥2 occasions or
thrombocytopenia <100.000/mm3 in the absence of
offending drugs.
Clinical manifestations were cumulative and referred to
the disease history.
2.2. Laboratory Evaluation. The study protocol included the
determination of autoantibodies and the evaluation of C3
and C4 serum levels. Specifically, ANA has been determined
by means of indirect immunofluorescence (IIF) on HEp-2
(titer ≥1 : 160 or ++ on a scale from + to ++++), anti-dsDNA
with IIF on Crithidia luciliae (titer ≥1 : 10), ENA (including
anti-Ro/SSA, anti-La/SSB, anti-Sm, and anti-RNP) by ELISA
assay considering titers above the cut-off of the reference
laboratory, anti-cardiolipin (anti-CL) (IgG/IgM isotype) by
ELISA, in serum or plasma, at medium or high titers (e.g.,
>40 GPL or MPL or above the 99th percentile), anti-𝛽2
Glycoprotein-I (anti-𝛽2GPI) (IgG/IgM isotype) by ELISA, in
serum (above the 99th percentile), and lupus anticoagulant
(LA) according to the guidelines of the International Society
on Thrombosis and Hemostasis (scientific subcommittee
on lupus anticoagulant/phospholipid-dependent antibodies)
[15]. Finally, C3 and C4 serum concentrations were studied
by means of radial immunodiffusion.
According to the anti-dsDNA status, we identified three
groups of patients:
(i) Anti-dsDNA +: SLE patients with persistent positiv-
ity.
(ii) Anti-dsDNA ±: SLE patients with initial positivity
and subsequent negativity during disease course.
(iii) Anti-dsDNA −: SLE patients with persistent negativ-
ity.
We evaluated all the patients at the last visit in our Lupus
Clinic. The antibodies status was assessed during the whole
disease course; consequently, antibodies status follow-ups
corresponded to the disease duration.
2.3. Statistical Evaluation. We used version 13.0 of the SPSS
statistical package. Normally distributed variables were sum-
marized using the mean ± standard deviation (SD) and non-
normally distributed variables were by themedian and range.
Percentages were used when appropriate.Mann-Whitney test
was performed accordingly. Univariate comparisons between
nominal variables were calculated using chi-square test or
Fisher’s test where appropriate. Two-tailed 𝑃 values were
reported; 𝑃 values less than 0.05 were considered significant.
3. Results
In the present study, we evaluated 393 SLE patients [29M/
364F (7.4%/92.6%); 386 (98.2%) Caucasian; mean age ± SD
44.8 ± 13.0 years; mean disease duration ± SD 152.4 ±
104.4 months]. Two hundred ninety-seven patients (75.6%)
showed a persistent or previous positivity for anti-dsDNA.
When grouping patients according to the anti-dsDNA sta-
tus, 245 patients (62.3%) were anti-dsDNA +, 52 (13.3%)
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Table 1: Demographic characteristics of the SLE patients (𝑁 = 393) according to the anti-dsDNA status.
Anti-dsDNA +
𝑁 = 245
Anti-dsDNA ±
𝑁 = 52
Anti-dsDNA −
𝑁 = 96
𝑃
Female – 𝑛 (%) 230 (93.9) 47 (90.4) 87 (90.6) a, b: 𝑃 = 0.2; c: 𝑃 = 0.5
Age (mean ± SD, years) 44.9 ± 13.6 43.8 ± 11.9 45.2 ± 12.2 a, c: 𝑃 = 0.2; b: 𝑃 = 0.8
Disease duration (mean ± SD, months) 12.6 ± 8.8 14.5 ± 9.5 11.9 ± 8.0 a: 𝑃 = 0.4; b: 𝑃 = 0.1; c: 𝑃 = 0.3
a: anti-dsDNA + versus anti-dsDNA ±; b: anti-dsDNA ± versus anti-dsDNA −; c: anti-dsDNA + versus anti-dsDNA −.
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Figure 1: Clinical features of the 245 (62.3%) anti-dsDNA + (group
1), 52 (13.3%) anti-dsDNA± (group 2), and 96 (24.4%) anti-dsDNA−
(group 3) SLE patients. ∗𝑃 = 0.001 group 1 versus group 2 and group
1 versus group 3; §𝑃 < 0.0001 group 3 versus group 1 and group 3
versus group 2.
anti-dsDNA ±, and 96 (24.4%) anti-dsDNA −. Regarding
anti-dsDNA ± subjects, anti-dsDNA antibodies became neg-
ative after amean period from the diagnosis of 8.5±8.3 years.
As reported in Table 1, no significant differences among
the three groups of patients were identified concerning
the sex distribution, the mean age, and the mean disease
duration.
We evaluated data concerning the distribution of the
clinical features (Figure 1), laboratory parameters (Figure 2),
and therapies (Figure 3) in the three groups of subjects.
The renal involvement was significantly more frequent
in the anti-dsDNA + patients (73 patients, 30.2%) compared
to anti-dsDNA ± (11 patients, 21.1%) and anti-dsDNA − (18
patients, 18.7%) (𝑃 = 0.001 for both comparisons, Figure 1).
Conversely, serositis resulted significantly more frequent in
the anti-dsDNA − (79 patients, 82.3%) compared to the anti-
dsDNA + and anti-dsDNA ± (51 (20.8%) and 7 patients
(13.4%), resp.; 𝑃 < 0.0001, Figure 1).
Concerning the immunological abnormalities (Figure 2),
the different autoantibodies showed a similar distribution
in the three groups except for the anti-RNP which were
significantlymore frequent in the anti-dsDNA+ and the anti-
dsDNA ± groups [45 (18.2%) and 9 (17.3%) patients, resp.],
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Figure 2: Immunological features distribution in the anti-dsDNA +
(group 1), anti-dsDNA ± (group 2), and 96 (24.4%) anti-dsDNA −
(group 3) SLE patients. ∗𝑃 = 0.04 group 1 versus group 3 and group 2
versus group 3; §𝑃 = 0.005 group 1 versus group 3 and group 2 versus
group 3.
compared with the anti-dsDNA − [7 patients (7.5%), 𝑃 = 0.04
for both comparisons]. Similarly, the reduction of C4 serum
levels resulted more frequent in the anti-dsDNA + and anti-
dsDNA ± [98 (40.0%) and 24 (44.2%) patients, resp.] than in
the anti-dsDNA – (21 (21.8%) patients; 𝑃 = 0.005 for both
comparisons, Figure 2).
In the anti-dsDNA +, we performed a comparison
between patients with and without anti-RNP antibodies:
patients with anti-RNP + showed more frequently skin
manifestations compared with those of anti-RNP negative
(70.0% versus 49.3%, 𝑃 = 0.02). Moreover, the frequency of
anti-Smwas higher in patients with anti-RNP compared with
negative patients (57.5% versus 4.6%, 𝑃 < 0.0001).
Finally, a similar therapeutical approach was applied
in the three patients groups, with similar percentage of
immunosuppressant drugs, except for cyclosporine A which
wasmore frequently prescribed in the anti-dsDNA+ patients
(60 patients, 24.5%) compared to anti-dsDNA ± and anti-
dsDNA − patients (9 (17.3%) and 12 (12.5%) patients, resp.;
𝑃 = 0.01; Figure 3).
Moreover, we focalized our attention on anti-dsDNA ±
(SLE patients with initial positivity and subsequent negativity
during disease course). In order to assess the disease activity
changes, we evaluated themean ECLAMvalues before (mean
follow-up 8.5 ± 8.3 years) and after (mean follow-up 4.3 ± 2.1
years) anti-dsDNA modification. No significant differences
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Figure 3: Therapies distribution of the 245 (62.3%) anti-dsDNA +
(group 1), 52 (13.3%) anti-dsDNA ± (group 2), and 96 (24.4%) anti-
dsDNA − (group 3) SLE patients. ∗𝑃 = 0.01 group 1 versus group 2
and group 1 versus group 2.
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Figure 4:Mean ECLAMvalues before (T0) and after (T1) modifica-
tion of anti-dsDNA status. Box andwhiskers plot (median, quartiles,
range, and possible extreme values).
were identified in the mean ECLAM values before and after
the return to negative results (1.0±1.3 versus 0.8±0.9,𝑃 = 0.7;
Figure 4). Moreover, the comparison of mean ECLAM values
between anti-dsDNA ± and anti-dsDNA + patients did not
show any significant difference (0.9 ± 1.05 versus 1.0 ± 0.9,
𝑃 = 0.8).
This result was confirmed indirectly by the evaluation
of treatment in this group of patients: 46.1% of the patients
maintained the same treatment regardless of the anti-dsDNA
modification. Nonetheless, 17.3% of the population who
become anti-dsDNA negative required the introduction of a
new immunosuppressant treatment.
4. Discussion
The results of the present study identified an association
between the persistent or previous positivity for anti-dsDNA
and specific clinical (kidney involvement) and immuno-
logical features (reduction of C4 serum levels, positivity
for anti-RNP antibodies). Conversely, patients negative for
anti-dsDNA seem to show a clinical picture characterized
by a higher prevalence of serositis. Moreover, the patients
experiencing the modification of anti-dsDNA status during
disease course do not appear to represent a specific subgroup.
SLE is an autoimmune disease, potentially involving any
organ/system, with a remitting-relapsing course [2, 16]. From
a pathogenetic point of view, the production of several
autoantibodies characterizes the disease. Among these, anti-
dsDNA represent the hallmark of SLE patients having a diag-
nostic value given their strong specificity [6, 7]. Moreover,
the presence of anti-dsDNA has been associated with a more
severe disease pattern characterized by renal involvement,
and a titer increase may predict a disease relapse [11, 12].
Despite these considerations about the role of anti-
dsDNA, a growing interest is devoted to other antibodies
detected in the serum of SLE patients, as evident by the
classification criteria recently proposed by the Systemic
Lupus International Collaborating Clinics [17, 18]. Indeed,
this new classification is characterized by the modification
of immunological items: autoantibodies other than anti-
dsDNA, such as anti-Sm, LA, anti-CL, and anti-𝛽2GPI, have
been considered as a single criterion, determining the greater
weight of these antibodies in the classification of SLE patients
[18].
On the other hand, data from the literature suggest
an association between different autoantibodies and spe-
cific clinical manifestations such as anti-dsDNA and lupus
nephritis, anti-SSA/SSB and sicca symptoms, and anti-RNP
and Raynaud’s phenomenon [7]. To and Petri in 2005
identified different autoantibody clusters in a large cohort
of SLE patients. The authors suggested that the Sm/RNP
cluster represents themost benign subset, withmore frequent
skin involvement and less common renal and hematological
manifestations. Conversely, the cluster anti-dsDNA/LA/anti-
CL is characterized by neuropsychiatric manifestations and
thrombotic events [19].
In the present cohort, we registered a frequency of
anti-dsDNA greater than 70% that is similar to the data
reported in the literature for otherCaucasian SLEpopulations
[7]. The persistent or previous positivity status for anti-
dsDNA seems to identify a SLE subset characterized by
the positivity for anti-RNP and the reduction of C4 serum
levels. Moreover, the significantly higher frequency of renal
involvement in persistently positive patients is in agreement
with data from the epidemiological studies, thus confirming
the pathogenetic role of anti-dsDNA in the kidney injury [9,
11, 20]. Furthermore, the associationwith lowC4 serum levels
confirms the link between anti-dsDNA and complement in
SLE patients with renal manifestations [21]. Recent evidence
suggests the influence of the complement receptors in the
development of anti-dsDNA by participating in clearance of
immune complexes and/or modulating B cells activation in
response to antigen [22].
The association with a higher frequency of anti-RNP
could be difficult to interpret. As known, patients affected by
mixed connective tissue disease are frequently positive for
these autoantibodies, with a frequency reaching 100% [7].
In SLE patients, the presence of anti-RNP ranges from 10 to
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30% and is associated with specific manifestations, such as
arthritis and Raynaud’s phenomenon [7].
Moreover, according to data from the abovementioned
analysis conducted by To and Petri, the Sm/RNP cluster
seems to be the most benign subset, with less common
renal involvement [19]. In our cohort, the presence of joint
involvement and Raynaud’s phenomenon is similar in the
three groups of patients. These results could be explained
by the different ethnicity in the cohorts evaluated. In the
previous cohort, less than 60% of SLE patients evaluated were
Caucasian; conversely, almost all SLE patients evaluated in
the present analysis are Caucasian [19].
Moreover, we analyzed the group of SLE patients per-
sistently negative for anti-dsDNA, identifying a significantly
higher frequency of serositis compared to the anti-dsDNA
positive patients. Data from the literature describe serositis
as a frequent SLE manifestation, especially as pericarditis
(8–48% of patients) and pleurisy (30–45%) [23]. In our
analysis, the frequency of serositis in persistently anti-dsDNA
negative patients resulted higher than 80%. Several authors
have reported the association between serositis and positivity
for anti-SSA/SSB antibodies, unconfirmed in our cohort
[7, 24]. Certainly, a limit to consider is the relatively small
number of patients in this group (96 subjects), determining
caution in the interpretation of the results. In the light of the
features of this group, a better analysis, by assessing larger
population, could be very attractive in order to characterize
these SLE patients and to modify some aspect strictly related
to the positivity for anti-dsDNA. For example, biological
drugs, such as belimumab, could be prescribed exclusively
in patients with positivity for anti-dsDNA, considering active
disease only in these patients.
A different genetic background could explain these dif-
ferences. SLE is a multifactorial disease in which genetic and
environmental factors interplay, determining disease devel-
opment [2, 25, 26]. The genetic background could explain
not only the disease susceptibility but also the autoantibodies
production. The genome-wide association study, conducted
by Chung and colleagues in 2011, demonstrated that many
previously identified SLE-associated genes are more strongly
associated with the production of anti-dsDNA than with
disease susceptibility [27]. The authors demonstrated the
association between polymorphisms (SNPs) located in the
MHC, STAT4, IRF5, and ITGAM regions and the positivity
for anti-dsDNA antibodies. Conversely, only SNPs in the
MHC and IRF5 regions have been identified in negative
patients [27]. These results suggested that some genetic
variants could be considered “autoantibody propensity loci”
rather than “SLE susceptibility loci” [27]. Finally, for the
first time the present study analyzed a peculiar group of
SLE patients, those with initial positivity and subsequent
negativity of anti-dsDNA. Some points to consider were
derived from the evaluation of this group. Firstly, the only
clinical and laboratory difference identified in patients who
become negative for anti-dsDNA compared to persistently
positive patients was a lower frequency of renal involvement.
Moreover, the modification of autoantibodies status was not
associated with a change in disease activity, as demonstrated
by the absence of significant difference in the mean ECLAM
values before and after the status change. We have chosen
to assess disease activity by ECLAM, because this index
does not include the anti-dsDNA determination among the
items evaluated, unlike other disease activity indices such
as SLE Disease Activity (SLEDAI) [28]. This observation is
reinforced by the evaluation of the therapeutical strategies
adopted in this group of patients after themodifications of the
anti-dsDNA status. Almost half of the patients maintained
the same treatment and 17.3% required the introduction
of a new immunosuppressant drug. Taken together these
results suggest that the presence of anti-dsDNA is associated
with a specific subset of disease with peculiar clinical and
laboratory features, which do not change when anti-dsDNA
become negative, maintaining similar aspect also in terms of
disease activity. On the contrary, the persistently anti-dsDNA
negative status seems to identify another subset of patients,
with peculiar clinical features, in particular serositis.
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